K. House

发表

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.

M. Kavuru, C. Laforce, B. Prillaman, 2000, The Journal of allergy and clinical immunology.

Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.

P. Dorinsky, J. Murray, R. Rosenthal, 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.

W. Silvers, S. Duke, C. Laforce, 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.

P. Dorinsky, R. Nathan, C. Scott, 2006, Clinical therapeutics.

Efficacy and Safety of Fluticasone Propionate/Salmeterol HFA 134A MDI in Patients with Mild‐to‐Moderate Persistent Asthma

P. Dorinsky, D. Peden, C. Scott, 2004, The Journal of asthma : official journal of the Association for the Care of Asthma.

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.

P. Dorinsky, S. Nimmagadda, C. Laforce, 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.

W. Lumry, J. Given, M. White, 2000, American journal of respiratory and critical care medicine.

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.

D. Peden, P. Mahajan, M. R. Thomas, 1998, The Journal of allergy and clinical immunology.

The Safety of Fluticasone propionate/Salmeterol Diskus® in Pediatric Patients Ages 4 –11 with Asthma

P. Dorinsky, J. Stauffer, K. House, 2004 .

Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.

P. Dorinsky, L. Boulet, P. Keith, 2007, Clinical therapeutics.

Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma

W. Lumry, G. Shapiro, J. Given, 2000 .

Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.

A. Woodcock, W. Busse, E. Bleecker, 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Phase III double‐blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple‐day cisplatin‐based chemotherapy

G. Sledge, L. Einhorn, K. House, 1992, Cancer.

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing

H. Ortega, P. Daley-Yates, D. Parkins, 2009, Clinical therapeutics.